-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Edgewise Therapeutics, Raises Price Target to $45

Benzinga·03/17/2026 14:32:59
Listen to the news
JP Morgan analyst Tessa Romero maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Overweight and raises the price target from $34 to $45.